EQL Pharma AB (publ) (FRA:7JK)

Market Cap	164.54M -19.1%
Revenue (ttm)	39.34M +25.8%
Net Income	2.71M -15.5%
EPS	0.09 -15.6%
Shares Out	n/a
PE Ratio	60.69
Forward PE	32.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	5
Open	5.55
Previous Close	5.52
Day's Range	5.44 - 5.55
52-Week Range	4.29 - 8.80
Beta	n/a
RSI	45.42
Earnings Date	Feb 3, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 55
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7JK

Financial Performance

In fiscal year 2025, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.

Financial numbers in SEK